ABC of Mens Health Blog

Men’s Health News
If you’re fishing for ways to reduce the risk of heart disease, you might start with the seafood-rich diet typically served up in Japan. According to new research, a lifetime of eating tuna, sardines, salmon and other fish appears to protect Japanese men against clogged arteries, despite other cardiovascular risk factors.
The research, published in the August 5, 2008, issue of Journal of the American College of Cardiology (JACC), suggests that the protection comes from omega-3 fatty acids found in abundance in oily fish. In the first international study of its kind, researchers found that compared to middle-aged white men or Japanese-American men living in the United States, Japanese men living in Japan had twice the blood levels of omega-3 fatty acids-a finding that was independently linked to low levels of atherosclerosis.
"The death rate from coronary heart disease in Japan has always been puzzlingly low," said Akira Sekikawa, M.D., Ph.D, an assistant professor of epidemiology at the University of Pittsburgh, PA, and an adjunct associate professor at Shiga University of Medical Science, Otsu, Japan. "Our study suggests that the very low rates of coronary heart disease among Japanese living in Japan may be due to their lifelong high consumption of fish."
Japanese people eat about 3 ounces of fish daily, on average, while typical Americans eat fish perhaps twice a week. Nutritional studies show that the intake of omega-3 fatty acids from fish averages 1.3 grams per day in Japan, as compared to 0.2 grams per day in the United States.
Earlier studies by Dr. Sekikawa’s team showed that Japanese men had significantly less cholesterol build-up in their arteries when compared to white men living in the United States-despite similar blood cholesterol and blood pressure readings, similar rates of diabetes and much higher rates of cigarette smoking. It was unclear, however, whether Japanese men were protected by strong genes, a high-fish diet or some other factor.
To answer that question, the ERA JUMP (Electron-Beam Tomography, Risk Factor Assessment Among Japanese and U.S. Men in the Post-World War II Birth Cohort) Study enrolled 868 randomly selected men aged 40 to 49. Of these, 281 were Japanese men from Kusatsu, Shiga, Japan; 306 were white men from Allegheny County, Pennsylvania; and 281 were third- or fourth-generation Japanese-American men from Honolulu, Hawaii.
All study participants had a physical examination, completed a lifestyle questionnaire, and had standard blood tests to evaluate cardiovascular health. Laboratory tests also measured total blood levels of fatty acids and the omega-3 fatty acids that come from fish (specifically, eicosapentaenoic, docosahexaenoic and docosapentaenoic acids).
In addition, researchers used two techniques to measure the level of cholesterol build-up in the arteries. In the first test, ultrasound waves gauged the thickness of the walls of the carotid arteries in the neck, a test known as intimal-medial thickness (IMT). In the second test, an electron-beam CT scanner measured calcium deposits, or "hardened" cholesterol, in the arteries of the heart, a test known as coronary artery calcification (CAC). Both have been shown to identify people at high risk for heart disease.
Dr. Sekikawa and his colleagues found that the total level of fatty acids was similar in the three groups, but the percentage represented by fish-based omega-3 fatty acids was two-fold higher in Japanese men living in Japan (9.2 percent) when compared to white men (3.9 percent) and Japanese-American men (4.8 percent) living in the United States.
The researchers also found that levels of atherosclerosis were similar in Japanese-American and white men, but markedly lower in Japanese men living in Japan. The average IMT was 37 µm less in Japanese than white men after age and cardiovascular risk factors were taken into account, while the average risk-adjusted difference in the proportion of Japanese and white men with positive CAC tests was 11 percent. Both gaps were highly significant, but became statistically insignificant when differences in omega-3 fatty acid levels were taken into account.
In Japanese men living in Japan the investigators also observed that IMT values went down as omega-3 fatty acid levels went up, an inverse relationship that was found to be statistically significant. This relationship between omega-3 fatty acid levels and IMT remained significant even after adjusting for traditional cardiovascular risk factors. (In Japanese men, CAC also went down as omega-3 fatty acid levels went up, but the relationship was not statistically significant.)
No significant inverse association between omega-3 fatty acid levels and atherosclerosis was observed in whites or Japanese-Americans once cardiovascular risk factors were accounted for.
"Our study clearly demonstrated that whites and Japanese-Americans have similar levels of atherosclerosis, which are much higher than in the Japanese in Japan," Dr. Sekikawa said. "This indicates that much lower death rates from coronary heart disease in the Japanese in Japan is very unlikely due to genetic factors."
The importance of the fish-derived omega-3 fatty acids in reducing risk for heart disease is powerfully underscored by this cross-cultural study, said William S. Harris, Ph.D., senior scientist and director of the Metabolism and Nutrition Research Center, Sanford Research/University of South Dakota, Sioux Falls. "Japanese men in Japan have equally bad or worse cardiovascular risk profiles as Americans, but less heart disease? How can this be?" said Dr. Harris, who was not involved in the ERA JUMP study. "What really distinguishes the Japanese men from the Americans is the fact that blood levels of the omega-3 fatty acids are twice as high in Japan as they are in the West.
"The take home message from this important study is this: Traditional risk factors lead to traditional amounts of artery-clogging plaque but only when the background diet, perhaps the lifetime diet, is chronically deficient in omega-3 fatty acids. Increase the omega-3 intake and heart disease rates in the West should begin to move closer to those in Japan. While it may take a high omega-3 diet from birth (as opposed to popping a few fish oil pills) to reach this goal, Dr. Sekikawa and his colleagues tell a compelling story that we would do well to heed."
Kaufen generishe viagra A follow-up study has recently been funded and will test the association of omega-3 fatty acids with the progression of atherosclerosis in white men, Japanese-American men, and Japanese men living in Japan.

generishe cialis soft pillen Ohne Rezept | generishe viagra soft pillen Ohne Rezept | generishe viagra online kaufen mastercard

Two men were sentenced on 21 May 2008 at Lewes Crown Court for the illegal sale and supply of an unlicensed medicine used to treat male erectile dysfunction under the Medicines Act 1968. The sentencing followed an investigation by the Medicines and Healthcare products Regulatory Agency (MHRA).
Colin Richard Hudson (52) of Hailsham, East Sussex was sentenced to eight months and two weeks imprisonment suspended for two years. Scott Hodgkiss (37) of Stoke-On-Trent, Staffordshire, received 120 hours community service. They had both previously pleaded guilty to a conspiracy charge under offences contrary to the Medicines Act 1968 concerning the illegal sale and supply of Kamagra on the Internet over a period of nearly seven months.
MHRA enquiries revealed that Mr Hodgkiss operated a website called www.kamagra100.co.uk. In February 2006, a search by MHRA enforcement officers of Mr Hodgkiss’ home address discovered a large quantity of Kamagra in tablet and jelly form with an estimated street value of ??23,000. Further investigation pointed to Mr Hudson as being Mr Hodgkiss’ supplier who was operating a website called www.kamagraman.co.uk. A search of Mr Hudson’s home address recovered documentation referring to Kamagra from his computer.
Mick Deats, Enforcement Group Manager at the MHRA said, "There is considerable risk to the public from obtaining medicines through unregulated websites. Buy lexapro without prescription The websites operated by Mr Hodgkiss and Mr Hudson were offering an unlicensed medicine. A medicine bought in this way has no guarantee of safety, quality or effectiveness."
Notes
1. The MHRA is the government agency responsible for ensuring that medicines and medical devices work, and are acceptably safe. No product is risk-free. Underpinning all our work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks. We keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem. We encourage everyone -the public and healthcare professionals as well as the industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action.
2. If an individual is convicted of offences under the Medicines Act 1968, they can be sentenced to a maximum of two years imprisonment and/or an unlimited fine. Where appropriate the MHRA will use the Proceeds of Crime Act 2002 to determine whether or not benefits were accrued through criminal activity and will recoup illicit earnings if the individual is found guilty.

Buy generic lasix | Generic propecia pills no prescription | Buy generic lexapro

NexMed, Inc. (Nasdaq: NEXM), announced the receipt of a non approvable letter from the U.S. Buy propecia pills Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for its topical treatment for erectile dysfunction (ED). The major regulatory issues raised by the FDA were related to the results of the transgenic mouse carcinogenicity study which NexMed completed in 2002.
Commenting on today’s announcement, Vivian Liu, President and Chief Executive Officer of NexMed said, "The transgenic mouse concern raised by the FDA is product specific, and does not affect the dermatological products in our pipeline. While we are disappointed by the FDA’s decision, the deficiencies cited in their letter were not unexpected. One positive outcome is the fact that the FDA did not cite the lack of completion of our long term open label safety study as a deficiency. We are encouraged that we do not need to redo this study, which would have taken up to 18 months to complete and at a substantial cost."
Hem Pandya, Vice President and Chief Operating Officer of NexMed added, "We remain committed to bringing our ED product to market, where there is a real demand from both patients and the urology community at large. As such, we plan to meet with the FDA and come to agreement on the necessary actions required in order to resubmit our NDA and resolve the deficiencies cited." Mr. Pandya further added, "We will also submit to the Agency final reports for two new, two-year carcinogenicity studies in both mice and rats, which were identified in the FDA’s letter as part of the information package needed to resolve the major deficiencies cited."
About NexMed
NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. Novartis is completing pivotal Phase 3 trials for NexMed’s NM100060, a novel onychomycosis treatment exclusively licensed to Novartis. In November 2007, the Company signed a U.S. licensing agreement for the ED Product with Warner Chilcott. NexMed’s pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.
NexMed, Inc.
Buy viagra pills | generic cialis online buy | Buy ultram without prescription

Men’s Health News
Researchers at The University of Nottingham have shown an association between certain past diagnostic radiation procedures and an increased risk of young-onset prostate cancer - a rare form of prostate cancer which affects about 10 per cent of all men diagnosed with the disease.
The study, the first of its kind to report the relationship between low dose ionising radiation from diagnostic procedures and the risk of prostate cancer, was funded by the Prostate Cancer Research Foundation (PCRF) and is part of the UK Genetic Prostate Cancer Study (UKGPCS). The results of the study have been published online in the British Journal of Cancer.
The study showed that men who had a hip or pelvic X-ray or barium enema 10 years previously were two and a half times more likely to develop prostate cancer than the general population. comprare il levitra senza ricetta And the link appeared to be stronger in men who had a family history of the disease.
The research was led by Professor Kenneth Muir, from the Division of Epidemiology and Public Health at The University of Nottingham, in association with Dr Rosalind Eeles at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Professor Muir said: "Although these results show some increase in the risk of developing prostate cancer in men who had previously had certain radiological medical tests we want to reassure men that the absolute risks are small and there is no proof that the radiological tests actually caused any of the cancers."
Four hundred and thirty one men, diagnosed with young onset prostate cancer - men diagnosed with the disease before the age of 60 - took part in the study.
The exposure to radiation was part of normal medical procedures which were performed 5, 10 or 20 years before diagnosis. Procedures included hip and leg X-rays, for example taken after an accident, and barium meals and enemas which are used to diagnose problems with the digestive system.
At this stage the evidence linking diagnostic radiation procedures and prostate cancer is still weak. This research suggests that further investigation into this link should be undertaken.
X-ray procedures used for diagnostic purposes deliver very small amounts of radiation per procedure. Their use is minimised in current medical practice. For most people X-rays do not increase the risk of developing cancer.

comprare il levitra pillole | comprare il cialis pillole | comprare viagra mastercard

For couples worldwide, erectile dysfunction (ED) is one of the leading contributors to a man’s inability to perform. As millions of men in America each year look for a solution, many seek alternative treatments to prescription medications and surgery that may have dangerous side effects. A new published study reveals that Prelox, a patented and proprietary blend of Pycnogenol, (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, combined with L-Arginine aspartate, an amino acid, is the natural answer to enhancing erectile quality.
The study, to be published in an upcoming edition of the International Journal of Impotence Research, shows improvement in men with ED after just one day. The study investigated the mechanism involved in relaxation of arteries as it is required for improved blood flow in erectile function. Prelox was found to cause a markedly increased nitric oxide production, the key mediator involved in expanding arteries for elevated blood flow during erections. By the end of the study, all men taking Prelox experienced almost a 100 percent increase of orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction.
Prelox is a patented unique blend of two circulation-enhancing ingredients including Pycnogenol, which contains powerful bioflavonoids that originate from plants and help keep blood vessels dilated for optimal blood flow. L-Arginine, an amino acid found in many foods, is the other ingredient coupled with Pycnogenol that ultimately promotes blood flow.
Pycnogenol and L-Arginine work together to enhance nitric oxide, a crucial chemical for sexual arousal, said Steven Lamm MD, from New York University School of Medicine Prelox is the perfect solution for men who want the same outcome as other prescription nitric oxide enhancers, but with a natural approach.
The randomized placebo-controlled study was conducted at the Medical University of Sofia, Bulgaria. Fifty patients with moderate erectile problems were asked to take two Prelox or placebo tablets in the morning and evening. The erectile quality of men was monitored using the same methodology as applied in clinical trial with pharmaceutical drugs - in a diary consisting of a questionnaire. In addition, semen, spermatozoa and blood samples were collected to measure nitric oxide and testosterone. The study consisted of a four-week period, followed by a wash-out period, another four-week period, and a final washout.
At the end of the treatment period, patients treated with Prelox achieved high questionnaire scores, whereas the placebo group had no significant effects. The erectile function score of men (mean age 37 years) at trial start was in average 14 out of a maximum 30. After one month on Prelox, the erectile function score increased to 27, which resembles almost completely healthy values such as those found in twenty year old men. Parallel to the increase of erectile function, the mean number of intercourse more than doubled during treatment for those who took Prelox. Treatment with Prelox produced a steep increase of nitric oxide activity in most patients and no changes were indicated for the placebo group.
This European study confirms my experience in a clinical trial with Prelox I carried out two years ago said Lamm. "This is the third clinical study showing that men can achieve greater erectile quality with Prelox, move past their performance anxiety and get more satisfaction from their sex lives."
Blood analysis revealed an increased testosterone level during supplementation with Prelox. This is not a direct result of the supplement but is typical for men with increased sexual activity. The men in this trial reported a dramatic increased frequency of morning erections. Moreover, their partners noted a higher interest for sex as well as better performance.
Past research on Prelox scientifically demonstrated its effectiveness in increasing and enhancing sexual performance in three clinical studies in the United States and Europe. In these studies, almost 85 percent of Prelox users said it improved erectile function and more than 70 percent of Prelox users said it was easier to initiate and sustain an erection. In a study at the New York University School of Medicine, more than 80 percent of male subjects rated Prelox as effective in improving their ability to engage in sexual activity.
Furthering evidence of its effectiveness, Prelox has been awarded a U.S. patent (U.S. 6,565,851 B2) for the relief of the symptoms of erectile dysfunction. NHS and Horphag Research have granted exclusive product licenses to several companies world-wide. Kaufen generishe cialis Horphag Research just announced a new partnership with Xion Corporation. Xion will launch Prelox to practitioners in North America.
Prelox is safe and easy to use "two tablets, twice a day for the first two weeks; then one to two tablets, twice a day to maintain and sustain enhanced pleasure and performance. Prelox is exclusively available at Purity Products , Herbalife, GVI and Xion. For more information visit
—————————-
Article adapted by Medical News Today from original press release.
—————————-
About Prelox
Prelox is a clinically tested and patented combination of two potent ingredients, L-Arginine aspartate, an amino acid that plays an important role in nitric oxide mechanisms in the body, and Pycnogenol, a natural plant extract originating from bark of the Maritime pine that grows along the coast of southwest France and expands and supports healthy blood vessels. Research shows that Prelox helps protect, restore and sustain blood flow to the genital area, naturally enhancing erections and the body’s sexual response. For more information, visit the Prelox Web site at
Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Prelox on behalf of Horphag Research. Prelox and Pycnogenol are registered trademarks of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #6,565,851 B2. NHS has the exclusive rights to market and sell Prelox in North America. For more information, visit the Prelox web site at
Source: Melanie Nimrodi
MWW Group
kaufen viagra soft Ohne Rezept | Kaufen generishe cialis soft | kaufen levitra Ohne Rezept